Contributions
Abstract: P894
Type: Poster
Abstract Category: Clinical aspects of MS - 6 MS and gender
Background: Several natural history studies have suggested worse outcomes in male patients with relapsing remitting multiple sclerosis (RRMS). Gender differences in treatment effect of disease modifying treatment is still unclear. We aim to describe gender differences in our multiple sclerosis (MS) patients in the era of disease modifying therapy.
Methods: A cross-sectional retrospective data analysis was performed on electronic clinical data collected from a state-level tertiary MS center after IRB approval. >90% of patients in the database had exposure to disease modifying agents.
Results: Of 857 patients with definite MS (F=621, M=235), 613 (71.6%) had RRMS; 179 (20.9%) had secondary progressive MS (SPMS), and 64 (7.5%) had primary progressive MS (PPMS). Males had a higher median EDSS of 3.0 compared to an EDSS of 2.0 for females (P=0.004). The median duration of disease was 9.6 years and 10.2 years for males and females respectively (P=0.788). Male patients were more likely to be diagnosed with PPMS than females (12.3% and 5.6% respectively, P=0.001). Of patients with RRMS or SPMS, males trended to have higher disability with a median EDSS of 3.0 compared to 2.0 for females, though this was not significant (P=0.058). For patients with RRMS or SPMS, male patients were more likely to be treated actively with disease modifying therapy, with 78.2% of men and 67.4% of females receiving active treatment (P=0.004). Male patients with RRMS or SPMS were more likely to be treated with aggressive agents (natalizumab, alemtuzumab, rituximab, cyclophosphamide, and mitoxantrone) at some point during their disease course when compared to females (38.7% and 28.2% respectively, P=0.005). No differences were observed between males and females for PPMS patients.
Conclusion: Male patients with MS are more likely to accumulate higher disability despite having a higher proportion of patients actively treated with disease modifying agents. They are also more likely to have a history of treatment with aggressive agents. No gender differences in disability accumulation were observed in PPMS patients.
Disclosure:
Andrew Bouley: nothing to disclose
Jonathan Cahill: nothing to disclose
Alison Daigle: nothing to disclose
Brian Wong: nothing to disclose
Roderick Elias: nothing to disclose
Syed Rizvi: nothing to disclose
Abstract: P894
Type: Poster
Abstract Category: Clinical aspects of MS - 6 MS and gender
Background: Several natural history studies have suggested worse outcomes in male patients with relapsing remitting multiple sclerosis (RRMS). Gender differences in treatment effect of disease modifying treatment is still unclear. We aim to describe gender differences in our multiple sclerosis (MS) patients in the era of disease modifying therapy.
Methods: A cross-sectional retrospective data analysis was performed on electronic clinical data collected from a state-level tertiary MS center after IRB approval. >90% of patients in the database had exposure to disease modifying agents.
Results: Of 857 patients with definite MS (F=621, M=235), 613 (71.6%) had RRMS; 179 (20.9%) had secondary progressive MS (SPMS), and 64 (7.5%) had primary progressive MS (PPMS). Males had a higher median EDSS of 3.0 compared to an EDSS of 2.0 for females (P=0.004). The median duration of disease was 9.6 years and 10.2 years for males and females respectively (P=0.788). Male patients were more likely to be diagnosed with PPMS than females (12.3% and 5.6% respectively, P=0.001). Of patients with RRMS or SPMS, males trended to have higher disability with a median EDSS of 3.0 compared to 2.0 for females, though this was not significant (P=0.058). For patients with RRMS or SPMS, male patients were more likely to be treated actively with disease modifying therapy, with 78.2% of men and 67.4% of females receiving active treatment (P=0.004). Male patients with RRMS or SPMS were more likely to be treated with aggressive agents (natalizumab, alemtuzumab, rituximab, cyclophosphamide, and mitoxantrone) at some point during their disease course when compared to females (38.7% and 28.2% respectively, P=0.005). No differences were observed between males and females for PPMS patients.
Conclusion: Male patients with MS are more likely to accumulate higher disability despite having a higher proportion of patients actively treated with disease modifying agents. They are also more likely to have a history of treatment with aggressive agents. No gender differences in disability accumulation were observed in PPMS patients.
Disclosure:
Andrew Bouley: nothing to disclose
Jonathan Cahill: nothing to disclose
Alison Daigle: nothing to disclose
Brian Wong: nothing to disclose
Roderick Elias: nothing to disclose
Syed Rizvi: nothing to disclose